429 related articles for article (PubMed ID: 22491229)
1. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
Braillon A; Dubois G
J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
[No Abstract] [Full Text] [Related]
2. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
3. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.
Pinsky PF; Miller E; Prorok P; Grubb R; Crawford ED; Andriole G
BJU Int; 2019 May; 123(5):854-860. PubMed ID: 30288918
[TBL] [Abstract][Full Text] [Related]
4. [Screening and prevention of prostate cancer].
Roosen A
MMW Fortschr Med; 2010 May; 152(19):37-9. PubMed ID: 20557000
[No Abstract] [Full Text] [Related]
5. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
[TBL] [Abstract][Full Text] [Related]
6. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
Carter HB
BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
Grubb RL; Pinsky PF; Greenlee RT; Izmirlian G; Miller AB; Hickey TP; Riley TL; Mabie JE; Levin DL; Chia D; Kramer BS; Reding DJ; Church TR; Yokochi LA; Kvale PA; Weissfeld JL; Urban DA; Buys SS; Gelmann EP; Ragard LR; Crawford ED; Prorok PC; Gohagan JK; Berg CD; Andriole GL
BJU Int; 2008 Dec; 102(11):1524-30. PubMed ID: 19035857
[TBL] [Abstract][Full Text] [Related]
8. Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Noordzij MA; Blanker MH
J Natl Cancer Inst; 2015 Jun; 107(6):djv110. PubMed ID: 25888716
[No Abstract] [Full Text] [Related]
9. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.
Taneja SS
J Urol; 2015 Jul; 194(1):113-4. PubMed ID: 26088223
[No Abstract] [Full Text] [Related]
10. [Early diagnosis of prostate cancer].
Hocaoglu Y; Seitz M; Stief CG; Bastian PJ
MMW Fortschr Med; 2012 Jan; 154(1):43-6. PubMed ID: 22642003
[No Abstract] [Full Text] [Related]
11. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC
J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052
[TBL] [Abstract][Full Text] [Related]
12. [Prostate cancer screening: Reasons of controversy].
Delporte G; Villers A; Penel N
Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer: Melbourne consensus-noble but misguided.
Ahmed HU
Nat Rev Urol; 2014 May; 11(5):250-1. PubMed ID: 24662731
[TBL] [Abstract][Full Text] [Related]
14. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.
Stampfer MJ; Jahn JL; Gann PH
J Natl Cancer Inst; 2014 Mar; 106(3):dju026. PubMed ID: 24610908
[No Abstract] [Full Text] [Related]
15. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
16. [Impact of PSA screening on mortality. PLCO project team (prostate, lung, colorectal, ovarian cancer screening trial)].
Heidenreich A; Nitschmann S
Internist (Berl); 2010 Feb; 51(2):219-20. PubMed ID: 20107755
[No Abstract] [Full Text] [Related]
17. [Prostate cancer screening benefit very low, even after 13 years].
Blanker MH; Noordzij MA
Ned Tijdschr Geneeskd; 2014; 158():A8349. PubMed ID: 25492737
[TBL] [Abstract][Full Text] [Related]
18. [Prostate cancer screening: no proof of the benefit].
Laplanche A; Hill C
Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
[No Abstract] [Full Text] [Related]
19. Response.
Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2015 Jun; 107(6):djv111. PubMed ID: 25888717
[No Abstract] [Full Text] [Related]
20. Guideline of guidelines: prostate cancer screening.
Loeb S
BJU Int; 2014 Sep; 114(3):323-5. PubMed ID: 24981126
[No Abstract] [Full Text] [Related]
[Next] [New Search]
